Commodore Capital LP
CIK 1831942 · Lihat di SEC EDGAR ↗
- Nilai Portofolio
- $1.7B
- Posisi
- 36
- Per tanggal
- 31 Maret 2026 Data per Q1 2026
#1.563 dari 8.643 berdasarkan nilai 13F · top 18.1%
Nilai portofolio QoQ: +15.1% 13F tidak mengungkapkan kas
- Bobot 10 kepemilikan teratas
- 68,18%
- Bobot 25 kepemilikan teratas
- 96,69%
- Posisi di atas 1%
- 22
- Jumlah posisi efektif
- 16,1
Berdasarkan kepemilikan ekuitas jangka panjang 13F saja (kas, obligasi, posisi jual tidak diungkapkan)
Perputaran Q2 2026: 10,73% Perkiraan pembelian $182.794.357 · penjualan $726.023.024
Kepemilikan median: 3,0 kuartal Dilacak Q4 2024–Q2 2026 · 46,5% masih dipegang
- Posisi baru
- 5
- Meningkat
- 6
- Menurun
- 9
- Tertutup
- 8
Di halaman ini
- Rincian sektor Bagaimana portofolio terbagi di berbagai sektor pasar.
- Portofolio Setiap saham yang dilaporkan dimiliki oleh institusi ini, dari 13F terbarunya.
- Taruhan baru terbesar Posisi baru yang dibuka pada kuartal terakhir.
- Pergerakan Teratas Peningkatan dan penurunan posisi terbesar pada kuartal ini.
- Posisi yang keluar Posisi yang sepenuhnya dijual oleh manajer pada kuartal lalu.
- Terkait Orang di balik pengaju ini, jika kami dapat mencocokkannya.
Rincian sektor
Healthcare
92,2%
Lainnya/Tidak terpetakan
7,8%
Portofolio lengkap 33 posisi
| Tipe | Rentetan | Tren 8 kuartal | |||||
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics, Inc. - Common Stock | $224.520.000 | 13,37% | 12.000.000 | $55.370.000 | Turun ×1 | ||
| ELVN Enliven Therapeutics, Inc. - Common Stock | $166.206.250 | 9,90% | 3.275.000 | $37.826.250 | |||
| ALKS Alkermes plc - Ordinary Shares | $157.185.000 | 9,36% | 3.000.000 | $8.673.000 | Turun ×1 | ||
| COGT Cogent Biosciences, Inc. - Common Stock | $118.035.000 | 7,03% | 3.050.000 | $6.875.611 | Naik ×2 | ||
| AMLX Amylyx Pharmaceuticals, Inc. - Common Stock | $101.474.000 | 6,04% | 5.650.000 | $22.939.000 | |||
| DFTX Definium Therapeutics, Inc. - Common Shares | $94.080.000 | 5,60% | 2.000.000 | $56.280.000 | |||
| SYRE Spyre Therapeutics, Inc. - Common Stock | $75.177.661 | 4,48% | 846.786 | $-21.282.786 | Turun ×2 | ||
| ANRO Alto Neuroscience, Inc. Common Stock | $71.865.142 | 4,28% | 2.723.196 | $10.647.696 | |||
| TNGX Tango Therapeutics, Inc. - Common Stock | $70.335.000 | 4,19% | 2.250.000 | ||||
| EYPT EyePoint, Inc. - Common Stock | $65.780.000 | 3,92% | 4.600.000 | $29.365.750 | Naik ×1 | ||
| TYRA Tyra Biosciences, Inc. - Common Stock | $59.887.500 | 3,57% | 1.875.000 | $-34.905.000 | Turun ×2 | ||
| GLTO Galecto, Inc. - Common Stock | $50.433.390 | 3,00% | 1.939.000 | $213.290 | |||
| CLDX Celldex Therapeutics, Inc. - Common Stock | $50.233.500 | 2,99% | 1.350.000 | $-35.303.160 | Turun ×1 | ||
| PHVS Pharvaris N.V. - Ordinary Shares | $49.276.500 | 2,93% | 1.425.000 | $-4.934.403 | Turun ×1 | ||
| LBRX LB Pharmaceuticals Inc - Common Stock | $48.682.500 | 2,90% | 1.500.000 | $11.692.500 | |||
| ASMB Assembly Biosciences, Inc. - Common Stock | $38.884.200 | 2,32% | 1.415.000 | $11.134.200 | Naik ×1 | ||
| EDIT Editas Medicine, Inc. - Common Stock | $28.800.360 | 1,72% | 8.889.000 | Naik ×1 | |||
| KYMR Kymera Therapeutics, Inc. - Common Stock | $28.667.500 | 1,71% | 250.000 | $-33.800.000 | Turun ×1 | ||
| CATX | $21.608.427 | 1,29% | 6.336.782 | $-4.815.954 | |||
| IPSC Century Therapeutics, Inc. - Common Stock | $21.304.347 | 1,27% | 8.695.652 | $1.652.173 | |||
| ZURA Zura Bio Limited - Class A Ordinary shares | $19.175.000 | 1,14% | 3.250.000 | $-162.500 | |||
| AVTX Avalo Therapeutics, Inc. - Common Stock | $18.818.535 | 1,12% | 1.018.319 | $11.607.345 | Naik ×1 | ||
| IFRX InflaRx N.V. - Common Stock | $16.352.000 | 0,97% | 7.300.000 | Naik ×1 | |||
| ANTX AN2 Therapeutics, Inc. - Common Stock | $14.199.011 | 0,85% | 2.933.680 | $6.217.713 | Naik ×1 | ||
| NUVL Nuvalent, Inc. - Class A Common Stock | $12.350.000 | 0,74% | 100.000 | $-73.052.320 | Turun ×1 | ||
| SABS SAB Biotherapeutics, Inc. - Common Stock | $11.193.000 | 0,67% | 2.870.000 | $-5.664.745 | Turun ×1 | ||
| IKT Inhibikase Therapeutics, Inc. - Common Stock | $10.956.901 | 0,65% | 5.397.488 | $1.889.121 | |||
| RLMD Relmada Therapeutics, Inc. - Common Stock | $9.861.000 | 0,59% | 1.425.000 | $5.449.049 | Naik ×1 | ||
| PEPG PepGen Inc. - Common Stock | $8.055.000 | 0,48% | 4.475.000 | $134.250 | |||
| Penerbit tidak dikenal (CUSIP: G75226103) | $5.350.000 | 0,32% | 500.000 | Naik ×1 | |||
| HLXC Helix Acquisition Corp. III - Class A Ordinary Shares | $5.320.000 | 0,32% | 500.000 | $240.000 | |||
| LONA LeonaBio, Inc. - Common Stock | $4.267.818 | 0,25% | 464.398 | $-506.193 | |||
| VTGN Vistagen Therapeutics, Inc. - Common Stock | $630.228 | 0,04% | 2.788.620 | ||||
| Tidak ada hasil | |||||||
Taruhan baru terbesar
Posisi baru dibuka kuartal ini, terbesar diurutkan pertama.
Penggerak teratas (QoQ)
| Sekuritas | Aksi | Saham Δ | Nilai Δ |
|---|---|---|---|
| DFTX | Hanya pergerakan harga | +0 | +$56.3M |
| RLAY | Dipangkas | -5.0M | +$55.4M |
| ELVN | Hanya pergerakan harga | +0 | +$37.8M |
| CLDX | Dipangkas | -1.3M | -$35.3M |
| TYRA | Dipangkas | -600K | -$34.9M |
| KYMR | Dipangkas | -500K | -$33.8M |
| EYPT | Beli lebih banyak | +1.8M | +$29.4M |
| AMLX | Hanya pergerakan harga | +0 | +$22.9M |
| SYRE | Dipangkas | -1.1M | -$21.3M |
| LBRX | Hanya pergerakan harga | +0 | +$11.7M |
1 posisi disembunyikan (pemeriksaan kelengkapan data)
Posisi yang keluar
Termasuk peristiwa perusahaan (merger, delisting) — tidak semua keluar adalah penjualan
Posisi tertutup mencerminkan perubahan pelaporan 13F; bagi manajer indeks, ini sering kali mekanis (penghapusan pencatatan, M&A, penyeimbangan ulang indeks), bukan keputusan aktif.
| Sekuritas | Kuartal | Saham sebelumnya | Nilai sebelumnya | Harga sejak keluar |
|---|---|---|---|---|
| MRUS | 31 Des. 2025 | 3.525.000 | $331.878.750 | Tidak lagi dilacak |
| AGIO | 31 Des. 2025 | 2.338.287 | $93.858.840 | 30,2% |
| VRDN | 31 Des. 2025 | 3.200.000 | $69.056.000 | -21,4% |
| PCVX | 30 Juni 2025 | 1.650.000 | $62.304.000 | 91,4% |
| TERN | 31 Maret 2026 | 1.475.000 | $59.590.000 | Tidak lagi dilacak |
| CDTX | 31 Des. 2025 | 585.000 | $56.019.600 | Tidak lagi dilacak |
| ORKA | 31 Maret 2026 | 1.753.054 | $53.135.067 | 123,3% |
| ERAS | 30 Juni 2026 | 3.175.000 | $51.371.500 | -1,5% |
| SRRK | 30 Sep. 2025 | 1.450.000 | $51.359.000 | 48,3% |
| XENE | 30 Juni 2026 | 825.000 | $47.973.750 | 5,9% |
| PTGX | 31 Maret 2026 | 450.000 | $39.303.000 | 49,6% |
| NRIX | 30 Juni 2026 | 2.275.000 | $35.262.500 | 13,3% |
| CRVS | 30 Juni 2026 | 2.258.735 | $33.045.293 | 3,9% |
| CTMX | 31 Maret 2026 | 7.692.300 | $32.769.198 | -25,1% |
| MNMD | 31 Maret 2026 | 2.000.000 | $26.780.000 | Tidak lagi dilacak |
| CNTA | 31 Maret 2026 | 1.000.000 | $25.010.000 | Tidak lagi dilacak |
| SLNO | 30 Juni 2026 | 652.432 | $21.843.423 | Tidak lagi dilacak |
| OCUL | 30 Juni 2026 | 2.575.000 | $21.810.250 | 16,4% |
| SLDB | 30 Juni 2025 | 5.825.000 | $21.552.500 | 99,3% |
| VERA | 30 Sep. 2025 | 800.000 | $18.848.000 | 13,6% |
| CRDF | 30 Juni 2025 | 5.384.616 | $16.907.694 | -71,3% |
| REPL | 31 Maret 2026 | 1.425.000 | $13.851.000 | 103,5% |
| TNGX | 31 Des. 2025 | 1.500.000 | $12.600.000 | 194,3% |
| PALI | 30 Juni 2026 | 7.181.062 | $12.566.859 | 3,3% |
| APGE | 31 Des. 2025 | 290.000 | $11.521.700 | 78,6% |
| ORIC | 30 Juni 2025 | 2.000.000 | $11.160.000 | 41,4% |
| KPTI | 30 Juni 2026 | 1.950.000 | $10.861.500 | -79,6% |
| ENTA | 31 Des. 2025 | 800.000 | $9.576.000 | -15,0% |
| ABVX | 31 Maret 2025 | 1.284.110 | $9.399.685 | 1821,0% |
| CTNM | 31 Maret 2026 | 816.326 | $9.330.606 | 14,7% |
| RAPT | 31 Maret 2026 | 250.000 | $8.467.500 | Tidak lagi dilacak |
| PCSC | 31 Des. 2025 | 750.000 | $7.920.000 | Tidak lagi dilacak |
| CELC | 30 Juni 2025 | 695.650 | $7.033.022 | 610,7% |
| NGNE | 30 Sep. 2025 | 427.866 | $6.396.597 | 115,2% |
| VTGN | 31 Des. 2025 | 1.575.000 | $5.591.250 | -63,3% |
| CBIO | 31 Des. 2025 | 450.829 | $5.360.357 | 46,7% |
| HLXB | 31 Maret 2025 | 500.000 | $5.250.000 | Tidak lagi dilacak |
| THRD | 31 Maret 2025 | 237.704 | $2.445.974 | Tidak lagi dilacak |
| DRUG | 31 Maret 2026 | 18.851 | $1.471.132 | 17,0% |
| NKTX | 31 Maret 2025 | 351.848 | $876.102 | 37,6% |